MCID: ESN002
MIFTS: 41

Eosinophilia-Myalgia Syndrome malady

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Eosinophilia-Myalgia Syndrome

About this section

Aliases & Descriptions for Eosinophilia-Myalgia Syndrome:

Name: Eosinophilia-Myalgia Syndrome 11 48 50 39 13 68
Ems 48 2
Syndrome with Inflammatory and Autoimmune Components That Affect the Skin, Fascia, Muscle, Nerve, Blood Vessels, Lung, and Heart 48
 
Severe Muscle Pain and Abnormally High Eosinophils 48
Eosinophilia Myalgia Syndrome 11
L-Tryptophan Induced Ems 48

Classifications:



External Ids:

Disease Ontology11 DOID:998
ICD9CM32 710.5
SNOMED-CT62 95416007
MeSH39 D016603

Summaries for Eosinophilia-Myalgia Syndrome

About this section
CDC:2 Emergency medical services (EMS) workers provide pre-hospital emergency medical care. Their duties create an inherent risk for on-the-job injuries and illnesses. Research shows that EMS workers have high rates of fatal injuries and nonfatal injuries and illnesses.

MalaCards based summary: Eosinophilia-Myalgia Syndrome, also known as ems, is related to fibrous histiocytoma and eosinophilia, and has symptoms including muscle cramp, muscle rigidity and muscle spasticity. An important gene associated with Eosinophilia-Myalgia Syndrome is IL5 (Interleukin 5), and among its related pathways are Th2 Differentiation Pathway and Inflammatory Response Pathway. Affiliated tissues include skin, heart and lung.

Wikipedia:71 Eosinophilia–myalgia syndrome (EMS) is an incurable and sometimes fatal flu-like neurological... more...

Related Diseases for Eosinophilia-Myalgia Syndrome

About this section

Diseases related to Eosinophilia-Myalgia Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 120)
idRelated DiseaseScoreTop Affiliating Genes
1fibrous histiocytoma29.7HLA-DRB1, IFNG
2eosinophilia11.1
3toxic oil syndrome10.5
4fasciitis10.5
5cholesteatoma of middle ear10.4IFNG, IL5
6thomsen and becker disease10.4IFNG, IL5
7gonococcal synovitis10.4IFNG, IL5
8acute gonococcal salpingitis10.4IFNG, IL5
9opiate dependence10.4IFNG, IL5
10cervix melanoma10.4IFNG, IL5
11idiopathic neutropenia10.4IFNG, IL5
12buphthalmos10.4IFNG, IL5
13tetanus neonatorum10.3IFNG, IL5
14granulomatous endometritis10.3IDO1, IL5
15x-linked intellectual disability, siderius type10.3IFNG, IL5
16sarcoid meningitis10.3IFNG, IL5
17compensatory emphysema10.3HLA-DQA1, IFNG
18eosinophilic fasciitis10.3
19wissler's syndrome10.3IFNG, IL5
20dengue disease10.3IFNG, IL5
21intrinsic cardiomyopathy10.3HLA-DQA1, IFNG
22gastric ulcer10.3IFNG, IL5
23churg-strauss syndrome10.3IFNG, IL5
24exophthalmos10.3IFNG, IL5
25conventional malignant hemangiopericytoma10.3IFNG, IL5
26blind hypotensive eye10.3IFNG, IL5
27liver carcinoma in situ10.3IDO1, IFNG
28calcifying epithelial odontogenic tumor10.3IDO1, IFNG
29psychologic dyspareunia10.2IDO1, IFNG
30lung sarcoma10.2IFNG, IL5
31alternating exotropia10.2IFNG, IL5
32arcus senilis10.2IFNG, IL5
33uterine corpus dissecting leiomyoma10.2IFNG, IL5
34deafness, autosomal recessive 6210.2IFNG, IL5
35bolivian hemorrhagic fever10.1HNMT, IFNG
36polyneuropathy10.1
37motion sickness10.1IFNG, IL5
38giant ganglionic hyperplasia10.1HLA-DRB1, IL5
39myopathy10.1
40neuropathy10.1
41purpura fulminans10.1HLA-DRB1, IL5
42wolffian duct adenocarcinoma10.1HLA-DQA1, HLA-DRB1
43parsonage turner syndrome10.1HLA-DQA1, HLA-DRB1
44myopathy-growth delay-intellectual disability-hypospadias syndrome10.1HLA-DQA1, HLA-DRB1
45ovarian papillary cystadenoma10.1HLA-DQA1, HLA-DRB1
46panuveitis10.0HLA-DQA1, HLA-DRB1
47autoinflammation, lipodystrophy, and dermatosis syndrome10.0HLA-DQA1, HLA-DRB1
48oculogyric crisis10.0HLA-DQA1, HLA-DRB1
49anthracosilicosis10.0HLA-DRB1, IFNG
50lymphocytic colitis10.0HLA-DRB1, IFNG

Graphical network of the top 20 diseases related to Eosinophilia-Myalgia Syndrome:



Diseases related to eosinophilia-myalgia syndrome

Symptoms & Phenotypes for Eosinophilia-Myalgia Syndrome

About this section

UMLS symptoms related to Eosinophilia-Myalgia Syndrome:


muscle cramp, muscle rigidity, muscle spasticity, pain, muscle weakness, myalgia

Drugs & Therapeutics for Eosinophilia-Myalgia Syndrome

About this section

Drugs for Eosinophilia-Myalgia Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
15-hydroxytryptophan13
2TryptophanNutraceutical62

Interventional clinical trials:

idNameStatusNCT IDPhase
1L-5-HTP-Related EMSCompletedNCT00001918
2Survey of the Use of Alternative Medical Therapies in Adult Cancer Patients Enrolled in Phase I Clinical TrialsCompletedNCT00001695

Search NIH Clinical Center for Eosinophilia-Myalgia Syndrome


Cochrane evidence based reviews: eosinophilia-myalgia syndrome

Genetic Tests for Eosinophilia-Myalgia Syndrome

About this section

Anatomical Context for Eosinophilia-Myalgia Syndrome

About this section

MalaCards organs/tissues related to Eosinophilia-Myalgia Syndrome:

36
Skin, Heart, Lung, Brain, T cells, Neutrophil, Liver

Publications for Eosinophilia-Myalgia Syndrome

About this section

Articles related to Eosinophilia-Myalgia Syndrome:

(show top 50)    (show all 338)
idTitleAuthorsYear
1
Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. (21702023)
2011
2
AHR activation by tryptophan--pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome? (19941898)
2010
3
Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms. (19790128)
2009
4
Part II. Eosinophilia-Myalgia Syndrome: further correlations between compromised histamine degradation, eosinophilias and myopathies. (17806156)
2007
5
Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome. (17892268)
2007
6
Calcinosis cutis in a patient with eosinophilia-myalgia syndrome: case report. (16838769)
2006
7
A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation. (16307217)
2005
8
Non-L-tryptophan related eosinophilia-myalgia syndrome with hypoproteinemia and hypoalbuminemia. (12610828)
2003
9
Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by the eosinophilia-myalgia syndrome. (11606145)
2001
10
Eosinophilic cholecystitis as a possible late manifestation of the eosinophilia-myalgia syndrome. (11147758)
2000
11
Is there any relationship between eosinophilia myalgia syndrome (EMS) and fibromyalgia syndrome (FMS)? An analysis of clinical and immunological data. (10721092)
1999
12
Eosinophilia-myalgia syndrome and giant cell myocarditis: a case report and therapeutic approach. (11720607)
1999
13
Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome. (10721088)
1999
14
Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. (10606395)
1999
15
Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. (10721089)
1999
16
On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome. (9817085)
1998
17
L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia. (9858150)
1998
18
Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome. (9787895)
1998
19
Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. (9544622)
1998
20
Pain, fatigue, and sleep in eosinophilia-myalgia syndrome: relationship to neuropsychological performance. (9706542)
1998
21
Neurologic, MR imaging, and MR spectroscopic findings in eosinophilia myalgia syndrome. (9802492)
1998
22
Eosinophilia myalgia syndrome. (9213377)
1997
23
On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome. (9295237)
1997
24
Eosinophilia-myalgia syndrome: selective cognitive impairment, longitudinal effects, and neuroimaging findings. (9408106)
1997
25
Eosinophilia-myalgia syndrome: description of an unusual case. (9196880)
1997
26
Elevated L-kynurenine level and its normalization by prednisolone in a patient with eosinophilia-myalgia syndrome. (9037890)
1997
27
Increased activity of the alpha 1(I) procollagen promoter in skin fibroblasts from patients with chronic eosinophilia-myalgia syndrome. (9076948)
1997
28
Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. (9375286)
1997
29
The eosinophilia myalgia syndrome: to be or not to be. (9213375)
1997
30
Eosinophilia-myalgia syndrome: opportunities realized and missed. (9195545)
1997
31
Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. (8895184)
1996
32
A contaminant of L-tryptophan enhances expression of dermal collagen in a murine model of eosinophilia myalgia syndrome. (8863345)
1996
33
Eosinophilia myalgia syndrome. The role of contaminants, the role of serotonergic metabolism set up. (8906288)
1996
34
Clinical features of eosinophilia myalgia syndrome and related disorders. (8906285)
1996
35
Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome. (8906289)
1996
36
Analysis of Centers for Disease Control and Prevention criteria for the eosinophilia-myalgia syndrome in a geographically defined population. (8895183)
1996
37
Eosinophilia-myalgia syndrome: patient status 2-4 years after onset. (8895178)
1996
38
Pathogenesis of L-tryptophan eosinophilia myalgia syndrome. (8906284)
1996
39
Criteria for the definition of the eosinophilia-myalgia syndrome. (8895176)
1996
40
Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases. (8895159)
1996
41
Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome. (8906287)
1996
42
A diagnostic algorithm for distinguishing the eosinophilia-myalgia syndrome from fibromyalgia and chronic myofascial pain. (8895177)
1996
43
Delayed onset of skin fibrosis after the ingestion of eosinophilia-myalgia syndrome-associated L-tryptophan. (8708033)
1996
44
EBT, a tryptophan contaminant associated with eosinophilia myalgia syndrome, is incorporated into proteins during translation as an amino acid analog. (9161698)
1996
45
Fibromyalgia, psychiatric disorders, and assessment of the longterm outcome of eosinophilia-myalgia syndrome. (8895180)
1996
46
Eosinophilia-myalgia syndrome. Status of patients at onset and after four years of disease. (8906291)
1996
47
The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels. (8906286)
1996
48
1995 Bailey K. Ashford lecture. Public health lessons from two catastrophic epidemics: the toxic oil syndrome and the eosinophilia-myalgia syndrome. (8744866)
1996
49
Eosinophilia-Myalgia Syndrome: Review and Reappraisal of Clinical, Epidemiologic and Animal Studies Symposium. Washington, D.C., USA, December 7-8, 1994. Proceedings. (9053528)
1996
50
The eosinophilia-myalgia syndrome: opportunities realized and missed. (8895138)
1996

Variations for Eosinophilia-Myalgia Syndrome

About this section

Expression for genes affiliated with Eosinophilia-Myalgia Syndrome

About this section
Search GEO for disease gene expression data for Eosinophilia-Myalgia Syndrome.

Pathways for genes affiliated with Eosinophilia-Myalgia Syndrome

About this section

GO Terms for genes affiliated with Eosinophilia-Myalgia Syndrome

About this section

Cellular components related to Eosinophilia-Myalgia Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1clathrin-coated endocytic vesicle membraneGO:00306699.8HLA-DQA1, HLA-DRB1
2endocytic vesicle membraneGO:00306669.8HLA-DQA1, HLA-DRB1
3ER to Golgi transport vesicle membraneGO:00125079.8HLA-DQA1, HLA-DRB1
4integral component of lumenal side of endoplasmic reticulum membraneGO:00715569.7HLA-DQA1, HLA-DRB1
5MHC class II protein complexGO:00426139.7HLA-DQA1, HLA-DRB1
6transport vesicle membraneGO:00306589.2HLA-DQA1, HLA-DRB1

Biological processes related to Eosinophilia-Myalgia Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of interleukin-12 productionGO:003273510.1IDO1, IFNG
2interferon-gamma-mediated signaling pathwayGO:00603339.4HLA-DQA1, HLA-DRB1, IFNG
3T cell receptor signaling pathwayGO:00508528.8HLA-DQA1, HLA-DRB1, IFNG

Molecular functions related to Eosinophilia-Myalgia Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1peptide antigen bindingGO:00426059.2HLA-DQA1, HLA-DRB1

Sources for Eosinophilia-Myalgia Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet